Literature DB >> 12396609

Optimal antigens for HIV vaccines based on CD8+ T response, protein length, and sequence variability.

Michael R Betts1, Karina Yusim, Richard A Koup.   

Abstract

The identification of optimal antigens to include in an HIV vaccine designed to elicit a cellular immune response requires careful consideration of protein length, variability, and immunogenicity. Here, we have examined the relationship of these parameters in a cohort of HIV-infected subjects. We find that HIV Gag and Nef represent optimal antigens for the CD8+ T cell response, based on size, variability, and immunogenicity. Although the Env and Pol proteins have a poorer response to length (Pol) or variability (Env) ratio than Gag or Nef, they are still strong candidates for inclusion into an HIV vaccine, based on overall response frequency in the cohort. The accessory proteins Tat, Rev, Vif, Vpr, and Vpu in general all elicit very low CD8+ T cell responses, and this, in combination with their high variability, makes them less attractive as vaccine antigen.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12396609     DOI: 10.1089/104454902760330200

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  6 in total

1.  Parallel human immunodeficiency virus type 1-specific CD8+ T-lymphocyte responses in blood and mucosa during chronic infection.

Authors:  F Javier Ibarrondo; Peter A Anton; Marie Fuerst; Hwee L Ng; Johnson T Wong; Jose Matud; Julie Elliott; Roger Shih; Mary Ann Hausner; Charles Price; Lance E Hultin; Patricia M Hultin; Beth D Jamieson; Otto O Yang
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

2.  Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individuals.

Authors:  Ellen R Van Gulck; Guido Vanham; Leo Heyndrickx; Sandra Coppens; Katleen Vereecken; Derek Atkinson; Eric Florence; Ilse Kint; Zwi Nisan Berneman; Viggo Van Tendeloo
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

3.  Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8+ T cells.

Authors:  Marybeth Daucher; David A Price; Jason M Brenchley; Laurie Lamoreaux; Julia A Metcalf; Catherine Rehm; Elizabeth Nies-Kraske; Elizabeth Urban; Christian Yoder; Diane Rock; Julie Gumkowski; Michael R Betts; Mark R Dybul; Daniel C Douek
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

4.  Estimate of within population incremental selection through branch imbalance in lineage trees.

Authors:  Gilad Liberman; Jennifer I C Benichou; Yaakov Maman; Jacob Glanville; Idan Alter; Yoram Louzoun
Journal:  Nucleic Acids Res       Date:  2015-11-19       Impact factor: 16.971

5.  Mucosal Vaccination with Heterologous Viral Vectored Vaccine Targeting Subdominant SIV Accessory Antigens Strongly Inhibits Early Viral Replication.

Authors:  Huanbin Xu; Anne-Marie Andersson; Emeline Ragonnaud; Ditte Boilesen; Anders Tolver; Benjamin Anderschou Holbech Jensen; James L Blanchard; Alfredo Nicosia; Antonella Folgori; Stefano Colloca; Riccardo Cortese; Allan Randrup Thomsen; Jan Pravsgaard Christensen; Ronald S Veazey; Peter Johannes Holst
Journal:  EBioMedicine       Date:  2017-03-08       Impact factor: 8.143

Review 6.  Virus-Like-Vaccines against HIV.

Authors:  Anne-Marie C Andersson; Melanie Schwerdtfeger; Peter J Holst
Journal:  Vaccines (Basel)       Date:  2018-02-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.